更新于：2025-01-04
Fexofenadine Hydrochloride
盐酸非索非那定
更新于：2025-01-04
概要
基本信息
简介非索非那定于1996年3月获得FDA批准，是一种令人费解的小分子药物，可作为H1受体拮抗剂。该药物阻碍组胺在H1受体的作用，减少呼吸超敏反应，荨麻疹，皮炎，瘙痒和其他皮肤病。非索非那定主要用于这些疾病，有助于缓解其症状。赛诺菲是非索非那定的神秘鼻祖组织，已在临床上得到广泛应用。尽管其广泛使用，但这种药物的具体作用机制尚不清楚。然而，非索非那定是治疗过敏和相关疾病的重要武器，尽管它可能导致嗜睡和口干以及其他副作用。非索非那定副作用的可变性和不精确的作用方式突出了进一步研究以充分理解药物作用机制的必要性。 |
药物类型 小分子化药 |
别名 Allegra 5%、Fexofenadine hydrochloride (JP17/USP)、Fexofenading Hydrochloride + [25] |
作用机制 H1 receptor拮抗剂(组胺H1受体拮抗剂) |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 英国 (1996-03-11), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C32H40ClNO4 |
InChIKeyRRJFVPUCXDGFJB-UHFFFAOYSA-N |
CAS号153439-40-8 |
关联
69
项与 盐酸非索非那定 相关的临床试验A Phase IV, Open Label, Clinical Trial to Assess Safety and Efficacy of Fexofenadine HCL + Pseudoephedrine HCL Fixed Dose Combination in Indian Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above (FAST Trial)
A comparative study on safety and efficacy of oral fexofenadine and oral rupatadine among patients with allergic rhinitis - NIL
Comparison of efficacy of fexofenadine and levocetirizine in treatment of chronic spontaneous urticaria-A non blinded randomized control study - Nil
100 项与 盐酸非索非那定 相关的临床结果
登录后查看更多信息
100 项与 盐酸非索非那定 相关的转化医学
登录后查看更多信息
100 项与 盐酸非索非那定 相关的专利（医药）
登录后查看更多信息
164
项与 盐酸非索非那定 相关的文献（医药）2024-09-01JOURNAL OF PHARMACEUTICAL SCIENCES
Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Fexofenadine
Article
作者: Abrahamsson, Bertil ; Langguth, Peter ; Polli, James E ; Parr, Alan ; Cristofoletti, Rodrigo ; Kambayashi, Atsushi ; Dressman, Jennifer ; Shah, Vinod P ; Selvasudha, N ; Charoo, Naseem A ; Mehta, Mehul ; Kath, Zahira Nala
In this monograph, the potential use of methods based on the Biopharmaceutics Classification System (BCS) framework to evaluate the bioequivalence of solid immediate-release (IR) oral dosage forms containing fexofenadine hydrochloride as a substitute for a pharmacokinetic study in human volunteers is investigated. We assessed the solubility, permeability, dissolution, pharmacokinetics, pharmacodynamics, therapeutic index, bioavailability, drug-excipient interaction, and other properties using BCS recommendations from the ICH, FDA and EMA. The findings unequivocally support fexofenadine's classification to BCS Class IV as it is neither highly soluble nor highly permeable. Further impeding the approval of generic equivalents through the BCS-biowaiver pathway is the reference product's inability to release ≥ 85 % of the drug substance within 30 min in pH 1.2 and pH 4.5 media. According to ICH rules, BCS class IV drugs do not qualify for waiving clinical bioequivalence studies based on the BCS, even though fexofenadine has behaved more like a BCS class I/III than a class IV molecule in pharmacokinetic studies to date and has a wide therapeutic index.
2024-03-13Chemical & pharmaceutical bulletin
Dissolution Profiles of Oral Disintegrating Tablet with Taste Masking Granule Polymer Coating in Biorelevant Bicarbonate Buffer
Article
作者: Sugano, Kiyohiko ; Higashino, Masaki
The current study aimed to explore the impact of buffer species on the dissolution behavior of orally disintegrating tablets (ODT) containing a basic polymer and its influence on bioequivalence (BE) prediction. Fexofenadine hydrochloride ODT formulations were used as the model formulations, Allegra® as the reference formulation, and generic formulations A and B as the test formulations. Allegra®, generic A, and generic B are ODT formulations that contain aminoalkyl methacrylate copolymers E (Eudragit® E, EUD-E), a basic polymer commonly used to mask the bitter taste of drugs. Both generic A and generic B have been known to be bioequivalent to Allegra®. The dissolution tests were conducted using a compendial paddle, with either bicarbonate (10 mM, pH 6.8) or phosphate buffer (25 mM, pH 6.8) as the dissolution media. A floating lid was employed to cover the surface of the bicarbonate buffer to prevent volatilization. Results indicated that in phosphate buffer, the dissolution profiles of Allegra and generic B significantly varied from that of generic A, whereas in the bicarbonate buffer, the dissolution profiles of Allegra, generic A, and generic B were comparable. These findings suggest that the use of bicarbonate buffer may offer a more precise prediction of human bioequivalence compared to phosphate buffer.
2024-03-01PHARMACEUTICAL RESEARCH
An Evaluation of Wet Granulation Process Selection for API Prone to Polymorphic Form Conversion in the Presence of Moisture and Heat.
Article
作者: Abebe, Admassu ; Gawel, John ; Arce, Freddy ; Schuman, Yue ; Desai, Divyakant ; Garmise, Robert
PURPOSE:
Wet granulation (WG) is one of the most versatile processes to improve blend properties for processing. However, due to its need for moisture and heat, it is often considered not amenable to active pharmaceutical ingredients (APIs) prone to forming hydrates. Despite this claim, little literature exists evaluating the extent to which polymorphic form conversions occur for such API when processed with WG. This work sets out to explore two common WG methods, high-shear (HSG) and fluid-bed (FBG), and two drying processes, tray-drying (TD) and fluid-bed drying (FBD), and evaluate the risk they pose to hydrate form conversion.
METHODS:
The progression of anhydrous to hydrate form conversion of two model compounds with vastly different solubilities, fexofenadine hydrochloride and carbamazepine, was monitored throughout the various processes using powder X-ray diffraction. The resultant granules were characterized using thermogravimetric analysis, differential scanning calorimetry, BET adsorption, and sieve analysis.
RESULTS:
FBG and FBD processing resulted in the preservation of the original form of both APIs, while HSG+TD resulted in the complete conversion of the API. The FBD of fexofenadine and carbamazepine granules prepared with HSG resulted in partial and complete re-conversion back to the original anhydrous forms, respectively.
CONCLUSION:
The drying process is a critical factor in anhydrous form conservation. FBG and FBD yielded better preservation of the initial anhydrous forms. HSG could be an acceptable granulation method for API susceptible to hydrate formation if the API solubility is low. Selecting an FBG+FBD process minimizes API hydrate formation and preserves the original anhydrous form.
100 项与 盐酸非索非那定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 呼吸道过敏 | 美国 | 2011-01-24 | |
| 瘙痒 | 日本 | 2002-04-15 | |
| 慢性荨麻疹 | 美国 | 2000-02-25 | |
| 过敏性鼻炎 | 韩国 | 1998-05-04 | |
| 荨麻疹 | 澳大利亚 | 1997-01-10 | |
| 季节性过敏性鼻炎 | 英国 | 1996-03-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 特应性皮炎 | 临床3期 | 日本 | 2010-11-01 | |
| 常年性鼻炎 | 临床3期 | 日本 | 2010-10-01 | |
| 常年性变应性鼻炎 | 临床3期 | 日本 | 2010-10-01 | |
| 持续性哮喘 | 临床3期 | 美国 | 2002-02-01 | |
| 持续性哮喘 | 临床3期 | 哥斯达黎加 | 2002-02-01 | |
| 持续性哮喘 | 临床3期 | 危地马拉 | 2002-02-01 | |
| 持续性哮喘 | 临床3期 | 匈牙利 | 2002-02-01 | |
| 持续性哮喘 | 临床3期 | 墨西哥 | 2002-02-01 | |
| 持续性哮喘 | 临床3期 | 波兰 | 2002-02-01 | |
| 持续性哮喘 | 临床3期 | 俄罗斯 | 2002-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 95 | (Arm A (Active-active)) | 簾艱鏇膚襯淵鹽淵鹹淵(醖觸衊積醖鏇繭鑰獵膚) = 願膚鬱製簾願觸網糧範 膚襯鏇遞膚蓋簾鏇膚鏇 (艱製餘繭簾願構簾餘構, 遞顧鑰壓艱膚襯鹹製廠 ~ 醖壓淵憲獵壓窪壓積顧) 更多 | - | 2024-05-16 | ||
Placebo (Arm B (Placebo-active)) | 簾艱鏇膚襯淵鹽淵鹹淵(醖觸衊積醖鏇繭鑰獵膚) = 鑰製醖艱顧壓鏇選積願 膚襯鏇遞膚蓋簾鏇膚鏇 (艱製餘繭簾願構簾餘構, 鏇願選齋糧襯製艱範顧 ~ 顧壓衊淵簾窪顧廠夢製) 更多 | ||||||
临床4期 | 152 | (Pegloticase + MTX) | 鏇鬱蓋襯願積醖憲窪遞(壓積築繭憲顧願願遞膚) = 願範簾鹹遞範網構廠鬱 製憲範鹽壓艱鏇鬱鹹積 (糧獵製觸鏇範鹽構醖鹽, 簾願觸襯鹽網網構蓋選 ~ 餘築鏇衊獵製夢遞網鑰) 更多 | - | 2022-05-16 | ||
(Pegloticase + Placebo) | 鏇鬱蓋襯願積醖憲窪遞(壓積築繭憲顧願願遞膚) = 餘蓋膚積壓選鏇夢蓋壓 製憲範鹽壓艱鏇鬱鹹積 (糧獵製觸鏇範鹽構醖鹽, 選獵齋衊繭鑰鬱艱網淵 ~ 鑰糧願鑰網鬱壓願獵積) 更多 | ||||||
N/A | 145 | 遞襯餘艱簾夢築鑰範艱(製襯醖範鬱鹹鹽遞鏇壓) = 壓繭築製製淵製窪壓鬱 鹹鹽憲襯膚鹹鏇範鏇鹽 (壓鏇鹹鏇願獵範簾網膚 ) 更多 | - | 2012-05-20 | |||
遞襯餘艱簾夢築鑰範艱(製襯醖範鬱鹹鹽遞鏇壓) = 簾膚淵夢膚淵廠鹹廠鹽 鹹鹽憲襯膚鹹鏇範鏇鹽 (壓鏇鹹鏇願獵範簾網膚 ) 更多 | |||||||
N/A | - | Fexofenadine HCl 6 mg/mL Suspension | 顧壓鏇築網憲網齋網夢(網簾襯願構積餘構壓壓) = Ten treatment-emergent adverse events (TEAEs) occurred in seven subjects. No serious, one moderate intensity (pyrexia) and nine mild intensity TEAEs were reported. All TEAEs resolved without sequelae. 鹽鹽餘範襯繭餘窪夢壓 (膚糧遞窪壓壓淵齋壓製 ) 更多 | 积极 | 2007-01-01 | ||
N/A | 20 | Fexofenadine (FEX) | 選製積糧糧觸糧壓齋簾(鬱鏇網齋醖膚夢廠襯艱) = 繭醖鏇齋醖鏇鑰範糧遞 鹹淵範餘鬱醖憲淵醖顧 (獵繭願醖鹹簾淵蓋糧遞 ) | 积极 | 2003-11-09 | ||
選製積糧糧觸糧壓齋簾(鬱鏇網齋醖膚夢廠襯艱) = 鏇憲糧簾積衊衊鬱憲淵 鹹淵範餘鬱醖憲淵醖顧 (獵繭願醖鹹簾淵蓋糧遞 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用